Drug disposition of chiral and achiral drug substrates metabolized by cytochrome P450 2D6 isozyme: case studies, analytical perspectives and developmental implications
- 15 June 2006
- journal article
- review article
- Published by Wiley in Biomedical Chromatography
- Vol. 20 (6-7) , 466-491
Abstract
The concepts of drug development have evolved over the last few decades. Although number of novel chemical entitities belonging to varied classes have made it to the market, the process of drug development is challenging, intertwined as it is with complexities and uncertainities. The intention of this article is to provide a comprehensive review of novel chemical entities (NCEs) that are substrates to cytochrome P450 (CYP) 2D6 isozyme. Topics covered in this review aim: (1) to provide a framework of the importance of CYP2D6 isozyme in the biotransformation of NCEs as stand‐alones and/or in conjunction with other CYP isozymes; (2) to provide several case studies of drug disposition of important drug substrates, (3) to cover key analytical perspectives and key assay considerations to assess the role and involvement of CYP2D6, and (4) to elaborate some important considerations from the development point of view. Additionally, wherever applicable, special emphasis is provided on chiral drug substrates in the various subsections of the review. Copyright © 2006 John Wiley & Sons, Ltd.Keywords
This publication has 184 references indexed in Scilit:
- Rapid determination of tramadol in human plasma by headspace solid-phase microextraction and capillary gas chromatography–mass spectrometryJournal of Pharmaceutical and Biomedical Analysis, 2005
- Simultaneous chiral analyses of multiple analytes: case studies, implications and method development considerationsBiomedical Chromatography, 2004
- Single-point plasma or urine dextromethorphan method for determining CYP3A activityBiopharmaceutics & Drug Disposition, 2003
- Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidolBritish Journal of Clinical Pharmacology, 2001
- Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genesBritish Journal of Clinical Pharmacology, 2000
- A sensitive assay of metoprolol and its major metabolite α-hydroxy metoprolol in human plasma and determination of dextromethorphan and its metabolite dextrorphan in urine with high performance liquid chromatography and fluorometric detectionJournal of Pharmaceutical and Biomedical Analysis, 1998
- Bioavailability and Disposition of Terodiline in ManJournal of Pharmaceutical Sciences, 1994
- Determination of debrisoquine 4-hydroxydebrisoquine in urine by high-performance liquid chromatography with fluorescence detection after solid-phase extractionJournal of Pharmaceutical and Biomedical Analysis, 1993
- Biotransformation of terodiline. v. stereoselectivity in hydroxylation by human liver microsomesChemico-Biological Interactions, 1989
- Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism) — Increased michaelis constant (km) and loss of stereoselectivity of bufuralol 1′-hydroxylation in poor metabolizersBiochemical and Biophysical Research Communications, 1984